Microsoft word - 2010 step therapy requirements.doc
2010 Step Therapy Criteria Effective January 1, 2010 Step Therapy Group Description Step Therapy Criteria
Requires member has filled at least a 60-day supply of a step 1 drug (i.e. long-acting beta agonist, Spiriva or inhaled corticosteroid) in the last 120 days before
Advair will be covered Requires member must have a documented 60-day trial of either Antabuse or naltrexone before Campral will
be covered Requires patient has tried and failed at least a 30 day trial on step 1 drug (i.e. fexofenadine, fluticasone nasal, Astelin or Astepro) within the last 120 days before Clarinex, Clarinex D, Patanase or Singulair will be
Requires patient have a prescription history demonstrating at least a six week trial each of at least two preferred step 1 drugs (i.e. citalopram, fluoxetine, bupropion, sertraline, paroxetine, fluvoxamine or
venlafaxine) before non-preferred agent will be covered
Requires patient has a prescription history demonstrating trial of risperdal and Seroquel before step
Requires member must have filled a 30-day supply of lamotrigine, valproate, topiramate or Felbatol in the last
Requires member has filled a prescription for at least 2
preferred generic antibiotics in the last 30-days Requires member has filled at least two prescriptions for step one drugs (i.e. generic equivalents) in the last 180
Requires patient has filled a prescription for generic hydrocodone/APAP or hydrocodone/IBU in the last
120-days Requires member has filled a prescription for a
macrolide in the last 30-days Requires member hs filled a prescription for at least two
non-COX 2 selective NSAIDs in the last 120-days Requires member has flled a prescription for a sulfonylurea, metformin (or combo agent), Actos,
ActoPlus Met, or Duetact within the last 120-days Requires member has filled a prescription for morphine sulfate sustained-release or Opana ER in the last 120-
2010 Step Therapy Criteria Effective January 1, 2010
Requires member has filled a prescription for a
protease-inhibitor, NRTI or NNRTI in the last 180-days Requires member has filled a prescription for preferred
PPI agent(s) in the last 150-days Requires member has filled a prescription for zolpidem
before Lunesta or Rozerem will be covered Requires member has filled a prescription for a long- acting stimulant and a short-acting stimulant within the
last 120-days Requires member has filled at least a 60-day supply of a step 1 drug (i.e. long-acting beta agonist, Spiriva or inhaled corticosteroid) in the last 120 days before
Symbicort will be covered Requires member has filled a prescription for a mealtime insulin in the last 120-days, and continues to
file meal-time insulin while on Symlin Member has filled a prescription for Vectical ointment
in the previous 120-days Requires member has filled 2 consecutive months of
allopurinol at maximum dose of 600mg per day Requires member has filled a prescription for
4815 West Markham Street-Little Rock, Arkansas 72205-3867-Telephone (501) 661-2000 Paul K. Halverson, DrPH, Interim Director Mike Huckabee, Governor July 28, 2005 Clostridium sordellii Toxic Shock Syndrome After Medical Abortion with Mifepristone and Intravaginal Misoprostol --- United States and Canada, 2001—2005; MMWR , July 22, 2005 On July 19, 2005, the Food and Drug
Boat technical features Overall length (Loa): 12,60 mt Beam : 4,10 mt Lenght hull: 11,98 mt Displacement laden : 10,00 ton Project category CE : B Number of passengers : 12 Semi-planing round hull with central keel Motorization VOLVO PENTA D4 turbo diesel common rail - 3.700 cc – 4 cylinders - 1 x 225 hp - line shaft VOLVO PENTA D6 turbo diesel common rail - 5.500 c